Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New appointments at Symphogen

This article was originally published in Scrip

Executive Summary

Symphogen, a private Danish biopharmaceutical company developing antibody therapeutics to treat cancer, and infectious and autoimmune diseases, has appointed Dr Ivan Horak chief scientific officer and medical officer and Gayle Mills chief business officer. Dr Horak joins from Enzon, where he was most recently president of R&D, having been chief scientific officer since 2005. Ms Mills had served as executive vice-president of business operations and chief business officer at Roxro Pharma for the past five years until the company's acquisition by Luitpold Pharmaceuticals, a subsidiary of Daiichi Sankyo.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012622

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel